The Biden Administration is looking to explore the emerging research of psilocybin to treat a variety of mental health illnesses as states across the country have started to decriminalize and legalize the substances for medical uses.
The administration anticipates the FDA to approve both MDMA and psilocybin as treatment for PTSD and depression within the next two years, and is “exploring the prospect of establishing a Federal Task Force” to monitor the drugs, according to a letter Miriam Delphin-Rittmon, the assistant secretary for mental health and substance use, sent to Rep. Madeleine Dean, D-Penn.